1.Generation and Evaluation of High beta-Glucan Producing Mutant Strains of Sparassis crispa.
Seung Rak KIM ; Hyeon Woo KANG ; Hyeon Su RO
Mycobiology 2013;41(3):159-163
A chemical mutagenesis technique was employed for development of mutant strains of Sparassis crispa targeting the shortened cultivation time and the high beta-glucan content. The homogenized mycelial fragments of S. crispa IUM4010 strain were treated with 0.2 vol% methyl methanesulfonate, an alkylating agent, yielding 199 mutant strains. Subsequent screening in terms of growth and beta-glucan content yielded two mutant strains, B4 and S7. Both mutants exhibited a significant increase in beta-glucan productivity by producing 0.254 and 0.236 mg soluble beta-glucan/mg dry cell weight for the B4 and S7 strains, respectively, whereas the wild type strain produced 0.102 mg soluble beta-glucan/mg dry cell weight. The results demonstrate the usefulness of chemical mutagenesis for generation of mutant mushroom strains.
Agaricales
;
Efficiency
;
Mass Screening
;
Mesylates
;
Methyl Methanesulfonate
;
Mutagenesis
;
Sprains and Strains
2.The authors' reply: Letter to the Editor: Cardiac arrest caused by nafamostat mesilate: Kounis syndrome in the dialysis room?.
Kidney Research and Clinical Practice 2017;36(1):107-107
No abstract available.
Dialysis*
;
Heart Arrest*
;
Mesylates*
3.Letter to the Editor: Cardiac arrest caused by nafamostat mesilate: Kounis syndrome in the dialysis room?.
Ioanna KONIARI ; Nicholas G KOUNIS
Kidney Research and Clinical Practice 2017;36(1):105-106
No abstract available.
Dialysis*
;
Heart Arrest*
;
Mesylates*
4.Data exclusivity through New Drug Reexamination in Korea: sibutramine hydrochloride (Reductil®) vs. sibutramine mesylate (Slimmer®) as an example
Translational and Clinical Pharmacology 2018;26(2):49-55
The ‘equivalent-or-more-but-not-the-same-data’ provision in the Regulation on the Safety and Efficacy Evaluation of New Drug in Korea has served as the de facto data exclusivity term for any drug identical to a product subject to new drug reexamination. The legal debate that occurred between Abbott Korea and Hanmi in association with the approval of their sibutramine products, i.e., Reductil® vs. Slimmer®, showed why data exclusivity plays an important role to protect intellectual property of the innovator drug when incrementally modified drugs had to rely on the safety and efficacy data of the innovator drug for approval. The regulatory science and legal issues regarding the case of Reductil® vs Slimmer® were discussed, and the importance of data exclusivity was emphasized as a useful tool to protect intellectual property besides patent.
Intellectual Property
;
Korea
;
Mesylates
5.Low-Dose Nafamostat Mesilate in Hemodialysis Patients at High Bleeding Risk.
Eun Yi KIM ; Young Ki LEE ; Seung Min LEE ; Myung Jin CHOI ; Young Rim SONG ; Soo Jin KIM ; Tae Jin PARK ; Sung Gyun KIM ; Jieun OH ; Jang Won SEO ; Jong Woo YOON ; Ja Ryong KOO ; Hyung Jik KIM ; Jung Woo NOH
Korean Journal of Nephrology 2011;30(1):61-66
PURPOSE: Systemic anticoagulation, usually with heparin, is required to prevent thrombosis in the blood circuit of hemodialysis. In patients at high bleeding risk, strategies to minimize the bleeding risk include heparin-free or regional anticoagulation methods. Nafamostat mesilate with conventional dose (35 mg/hr) has been used for this purpose. But it is an expensive anticoagulant to use conveniently for the dialysis therapy. Application of low-dose nafamostat mesilate has almost never been tried yet on hemodiaysis management. In this study, we examined the effect of low-dose nafamostat mesilate compared to heparin-free in hemodialysis patients with high risk of bleeding. METHODS: The current study was conducted on 35 hemodialysis patients with high bleeding risk (on-going bleeding, hemorrhage, surgery or severe thrombocytopenia). In the low-dose nafamostat group (n=17, mean age: 59+/-15 years), 238 sessions were performed with continuous infusion of nafamostat mesilate (12.5 mg/hr). In the control group with saline-flushing no heparin methods (n=18, mean age: 57+/-17 years), 247 sessions were analyzed. RESULTS: No significant differences were found in baseline characteristics between the low-dose nafamostat group and the saline group. In the progress of bleeding complications, there were no significant differences between the two groups (11.8% vs. 11.1%). In saline group, however, massive clotting occurred in 44.5 per 1000 sessions, while it occurred in 4.2 per 1000 sessions in the low-dose nafamostat group (p=0.006). CONCLUSION: In patients at high bleeding risk, low-dose nafamostat mesilat can be used as an inexpensive, effective, and safe anticoagulant for hemodialysis.
Dialysis
;
Guanidines
;
Hemorrhage
;
Heparin
;
Humans
;
Mesylates
;
Renal Dialysis
;
Thrombosis
6.Plantar Keratoderma with Pachyonychia Likely Induced by Imatinib Mesylate.
Hyung Ok KIM ; Bo In LEE ; Jun Young LEE ; Young Min PARK
Annals of Dermatology 2013;25(4):526-528
No abstract available.
Benzamides
;
Mesylates*
;
Nails, Malformed*
;
Piperazines
;
Pyrimidines
;
Imatinib Mesylate
7.Lichenoid Drug Eruption after Low-Dose Imatinib Mesylate Treatment.
Jae Hyung LEE ; Jong Yoon CHUNG ; Mi Young JUNG ; Cho Rok KIM ; Ji Ho PARK ; Ji Hye PARK ; Jong Hee LEE ; Joo Heung LEE ; Jun Mo YANG ; Dong Youn LEE
Annals of Dermatology 2013;25(4):500-502
No abstract available.
Benzamides
;
Drug Eruptions*
;
Mesylates*
;
Piperazines
;
Pyrimidines
;
Imatinib Mesylate
8.A Multi-Center Phase III Clinical Trial to Assess the Influence to Bleeding and Anticoagulant Effect of Nafamostat Mesilate (Futhan) in Hemodialysis Patients with High Bleeding-Risk.
Hyun Chul KIM ; Seung Yeup HAN ; Hyung Kyu KIM ; Won Yong CHO ; Soo Ah SUNG ; Su Kil PARK ; Jae Won CHANG
Korean Journal of Nephrology 2004;23(6):920-926
BACKGROUND: Routine hemodialysis is performed with systemic anticoagulation, usually with heparin, to prevent thrombosis in the extracorporeal blood circuit. However, systemic anticoagulation can produce hemorrhagic complications in patients at high risk of bleeding. To minimize the risk of bleeding, a number of alternative regimens has been proposed, however, each of those methods has its own limitations and complication. METHODS: 58 hemodialysis patients at risk for bleeding due to previous surgery or hemorrhagic complication were treated with Futhan as regional anticoagulant and compared with that of low-dose heparin anticoagulation. There were 29 (50%) postoperative cases and 29 (50%) cases of hemorrhage from various sites. RESULTS: The exacerbation of bleeding by hemodialysis was noted in only 4% in heparin treated group and none in Futhan group. Clotting times at site A (intracorporeal circulation) were not prolonged with Futhan, whereas those of heparin were prolonged slightly, which is not statistically significant. Degrees of residual blood in the dialyzer and blood clottings in the venous drip-chamber were less in Futhan than in heparin group. Adverse reactions related to Futhan therapy were minor and the incidence of adverse reactions was comparable in both groups. CONCLUSION: Futhan is a safe and effective regional anticoagulant for hemodialysis especially for patients with high bleeding risk.
Blood Coagulation
;
Hemorrhage*
;
Heparin
;
Humans
;
Incidence
;
Mesylates*
;
Renal Dialysis*
;
Thrombosis
9.Micro-needle knife in treatment of cervical vertigo and its effect on vertebral artery hemodynamics.
Jian-Chang LUO ; Luo-Dan WANG ; Wen-Bin XU ; Bo-Xu LANG
Chinese Acupuncture & Moxibustion 2022;42(8):844-848
OBJECTIVE:
To compare the effect of micro-needle knife therapy and betahistine mesilate tablets in the treatment of cervical vertigo (CV) and the influence on the mean blood flow velocity (Vm) of vertebral artery.
METHODS:
A total of 200 patients with CV were randomly divided into a micro-needle knife group (100 cases, 5 cases dropped off) and a medication group (100 cases, 3 cases dropped off). In the micro-needle knife group, micro-needle knife was performed on the suboccipital triangle of the atlantoaxial segment of the posterior neck, once every other day, for a total of 7-time treatment. The medication group received oral betahistine mesilate tablets, 6 mg each time, three times a day, for 14 consecutive days. The dizziness handicap inventory (DHI) scores of the two groups were observed before treatment, after treatment and during follow-up 3 months after treatment; the Vm of vertebral artery was compared between the two groups before and after treatment, and the clinical effect was evaluated during follow-up.
RESULTS:
After treatment and during follow-up, the DHI scores of the two groups were lower than those before treatment (P<0.001), and those in the micro-needle knife group were lower than the medication group (P<0.001). After treatment, the Vm of bilateral vertebral arteries in both groups was higher than that before treatment (P<0.05), and that in the micro-needle knife group was higher than the medication group (P<0.05). The total effective rate of the micro-needle knife group was 96.8% (92/95), which was higher than 67.0% (65/97) of the medication group (P<0.001).
CONCLUSION
Micro-needle knife therapy can improve vertigo symptoms and balance dysfunction, increase the mean blood flow velocity of vertebral artery in CV patients, and its clinical efficacy is better than oral betahistine mesilate tablets.
Betahistine
;
Hemodynamics
;
Humans
;
Mesylates
;
Treatment Outcome
;
Vertebral Artery
;
Vertigo/therapy*
10.Open-label, Randomized Comparison of the Efficacy of Intravenous Dolasetron Mesylate and Ondansetron in the Prevention of Acute and Delayed Cisplatin-induced Emesis in Cancer Patients.
Jin Soo KIM ; Ji Yeon BAEK ; Sook Ryun PARK ; In Sil CHOI ; Sang Il KIM ; Dong Wan KIM ; Seock Ah IM ; Tae You KIM ; Dae Seog HEO ; Yung Jue BANG ; Noe Kyeong KIM
Cancer Research and Treatment 2004;36(6):372-376
PURPOSE: The aim of this study is to compare the antiemetic efficacy and tolerability of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed emesis. MATERIAL AND METHODS: From April 2002 through October 2002, a total of 112 patients receiving cisplatin- based combination chemotherapy were randomized to receive a single i.v. dose of dolasetron 100 mg or ondansetron 8 mg, 30 minutes before the initiation of chemotherapy. In the ondansetron group, two additional doses of ondansetron 8 mg were given at intervals of 2 to 4 hours. To prevent delayed emesis, dolasetron 200 mg p.o. daily or ondansetron 8 mg p.o. bid was administered from the 2nd days to a maximum of 5 days. The primary end point was the proportion of patients that experienced no emetic episodes and required no rescue medication (complete response, CR) during the 24 hours (acute period) and during Day 2 to Day 5 2 days (delayed period), after chemotherapy. The secondary end points included the incidence and severity of emesis. RESULTS: 105 patients were evaluable for efficacy. CR rates during the acute period were 36.0% for a single dose of dolasetron 100 mg, and 43.6% for three doses of ondansetron 8 mg. CR rates during the delayed period were 8.0% and 10.9%, respectively. There was no significant difference in the efficacy between the two groups. Adverse effects were mostly mild to moderate and not related to study medication. CONCLUSIONS: A single i.v. dose of dolasetron 100 mg is as effective as three i.v. doses of ondansetron 8 mg in preventing acute and delayed emesis after cisplatin- based chemotherapy, with a comparable safety profile.
Antiemetics
;
Drug Therapy
;
Drug Therapy, Combination
;
Humans
;
Incidence
;
Mesylates*
;
Nausea
;
Ondansetron*
;
Vomiting*